Clinical Trials
22 trialsNCT00544115 2026-06-02
Donor Peripheral Stem Cell Transplant in Treating Patients With Advanced Hematologic Cancer or Other Disorders
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04803201 2026-06-02
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 2 Suspended
NCT03017820 2026-05-28
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Phase 1 Recruiting
NCT03598998 2026-05-26
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
City of Hope Medical Center
Phase 1/2 Active not recruiting
NCT07055477 2026-05-22
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT07388563 2026-05-08
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
Phase 1 Suspended
NCT05377827 2026-05-06
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies
Washington University School of Medicine
Phase 1 Active not recruiting
NCT06035497 2026-05-01
A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Bristol-Myers Squibb
Phase 1/2 Active not recruiting
NCT06561048 2026-04-08
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Corvus Pharmaceuticals, Inc.
Phase 3 Recruiting
NCT06522737 2026-04-06
TERZO
SecuraBio
Phase 3 Recruiting
NCT06692452 2026-04-01
Tazemetostat Plus CHOP in 1L T-cell Lymphoma
Dana-Farber Cancer Institute
Phase 2 Withdrawn
NCT07300514 2026-03-31
T-START-M1
Fudan University
Phase 3 Recruiting
NCT03590574 2026-03-16
Phase I/II Study Evaluating AUTO4 in Patients With T Cell Receptor Beta Constant (TRBC)1 Positive T Cell Lymphoma
Autolus Limited
Phase 1/2 Terminated
NCT06393738 2026-02-10
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Arvinas Inc.
Phase 1 Recruiting
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT03278782 2026-01-09
Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT01787409 2025-12-30
Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency
Mayo Clinic
Phase NA Active not recruiting
NCT02223208 2025-12-02
FIL_PTCL13
Fondazione Italiana Linfomi - ETS
Phase 1/2 Active not recruiting
NCT02588651 2025-11-21
A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03113500 2025-11-14
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
City of Hope Medical Center
Phase 2 Active not recruiting
NCT04234048 2025-09-22
Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
SciTech Development, Inc.
Phase 1 Recruiting
NCT00935090 2025-07-08
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Barbara Ann Karmanos Cancer Institute
Recruiting